Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRGF for Vulvar Lichen Sclerosus
NCT05364515Phase 3Withdrawn
- Sponsor
- Fundación Eduardo Anitua
- Start
- Dec 2021
- Primary completion
- Feb 2024
- Modality
- Cell Therapies
01
Overview
Phase 3, randomised trial of PRGF-Endoret in vulvar lichen sclerosus (LS) (2 arms), sponsored by Fundación Eduardo Anitua. Primary endpoint: Evolution of quality of life measured by Skindex-29 index at 8 months. Planned start Dec 2021; status: withdrawn.
02
Drugs
PRGF-Endoret
03
Conditions
vulvar lichen sclerosus (LS)
Beyond the preview
Go deeper on NCT05364515.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364515.